Education
About Us
Working with TipRanks
Follow Us
CareDx (CDNA)
NASDAQ:CDNA
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.19Same Quarter Last Year
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted robust top-line growth, significant improvements in cash collections and RCM execution, sustained gross margins, meaningful product and regulatory progress (including promising cell therapy surveillance data), and a clean balance sheet with active share repurchases. Near-term headwinds include one-time compensation charges, guidance conservatism, reimbursement risk from a draft LCD and a PLA reimbursement reduction, and planned investments (Epic/LIMS) that will pressure near-term EBITDA. Overall, the company presents positive operational momentum and a clear plan to invest for future scaled growth while prudently modeling reimbursement and volume risks into 2026 guidance.Company Guidance
Strong Q4 and FY Revenue Growth
Q4 2025 total revenue of $108.4M, up 25% year-over-year; full year 2025 revenue of $379.8M, up 14% year-over-year.
Testing Volume and Testing Services Momentum
Q4 testing volume ~53,000 tests, up 17% year-over-year; Q4 Testing Services revenue $78.4M (+23% YoY). Full year testing volumes ~200,000, up 14% and Testing Services revenue $274.5M (+10% YoY).
Improved Cash Collection and Receivables Metrics
Full year 2025 cash collections $405.6M, up 32% YoY; Q4 collections $115.8M, up 37% YoY. Accounts receivable reduced by $22.5M year-over-year and DSO improved from 71 to 41 days (42% improvement).
Healthy Gross Margins and Profitability Progress
Q4 non-GAAP gross profit $74.3M (68.5% gross margin). Full year gross margin ~69.3%, consistent year-over-year. Full year 2025 adjusted EBITDA $31.7M, up 14% YoY.
Product and Regulatory Milestones
Launched AlloSure Heart for Pediatrics, Alisure Plus (AI kidney risk model), HistoMAP Kidney tissue-based classifier; launched AlloSeq TX11 and SCOR 7; achieved IVDR certification for AlloSeq TX and QType in Europe.
Compelling Cell Therapy (Allaheme) Clinical Data
ACROBAT results: Allaheme detected relapse a median 41 days earlier, with 85% sensitivity and 92% specificity; positive 6-month result associated with a 12-fold higher relapse risk. CLIA readiness targeted in 2026 with commercial introduction planned for early 2027.
Patient & Digital Solutions and Lab Products Acceleration
Q4 Patient & Digital Solutions revenue $16.8M (+47% YoY); Q4 Lab Products revenue $13.3M (+17% YoY). Full year Patient & Digital Solutions revenue $56.9M (+31% YoY); Lab Products $48.4M (+19% YoY).
Strong Balance Sheet and Share Repurchases
Ended year with $201.4M in cash, cash equivalents, and marketable securities and no debt. Repurchased $88.0M of common stock in 2025 (5.8M shares) and an additional $12.0M in Q4.
CDNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CDNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | $14.52 | $16.53 | +13.84% |
Aug 06, 2025 | $13.10 | $12.07 | -7.86% |
Apr 30, 2025 | $16.88 | $15.07 | -10.72% |
Feb 26, 2025 | $21.10 | $21.06 | -0.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does CareDx (CDNA) report earnings?
CareDx (CDNA) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is CareDx (CDNA) earnings time?
CareDx (CDNA) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CDNA EPS forecast?
CDNA EPS forecast for the fiscal quarter 2026 (Q1) is -0.04.
